Soluble Fas: A novel predictor of atherosclerosis in dialysis patients

American Journal of Kidney Diseases

Volumn 41, Issue 5, 2003, Pages 1043-1051

  Troyanov, Stéphan ^b   Hébert, Marie Josée ^b   Masse, Mélanie ^b   Vigneault, Normand ^b   Sirois, Isabelle ^b   Madore, François ^a  

^a HÔPITAL DU SACRÉ COEUR DE MONTRÉAL   (Canada)

^b NONE

Author keywords

Apoptosis; Atherosclerosis; Cardiovascular disease (CVD); Dialysis; Inflammation; Soluble Fas (sFas)

Indexed keywords

C REACTIVE PROTEIN; FAS LIGAND; INTERCELLULAR ADHESION MOLECULE 1;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; COHORT ANALYSIS; DIABETES MELLITUS; FEMALE; HEMODIALYSIS PATIENT; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PROSPECTIVE STUDY; RISK FACTOR; SMOKING;

AGED; ANTIGENS, CD95; ARTERIOSCLEROSIS; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; FEMALE; FOLLOW-UP STUDIES; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; RENAL DIALYSIS; RISK FACTORS;

EID: 0037741801     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0272-6386(03)00202-6     Document Type: Article

References (42)

1. Canadian Organ Replacement Register (CORR): Annual Report, vol 1: Dialysis and Renal Transplantation (data 1981-1999). Ottawa, Ontario, CORR, 2001
2. US Renal Data System: USRDS 1999 Annual Data Report. The National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 1999
3. ERA-EDTA: Annual Report on Management of Renal Failure in Europe. London, UK, ERA-EDTA Registry, 1997
4. Libby P: Changing concepts of atherogenesis. J Intern Med 247:349-358, 2000
5. Ross R: Atherosclerosis - An inflammatory disease. N Engl J Med 340:115-126, 1999
6. Chisolm GM, Steinberg D: The oxidative modification hypothesis of atherogenesis: An overview. Free Radic Biol Med 28:1815-1826, 2000
7. Geng YJ: Biologic effect and molecular regulation of vascular apoptosis in atherosclerosis. Curr Atherosclerosis Rep 3:234-242, 2001
8. Choy JC, Granville DJ, Hunt DW, et al: Endothelial cell apoptosis: Biochemical characteristics and potential implications for atherosclerosis. J Mol Cell Cardiol 33:1673-1690, 2001
9. Pollman M, Hall J, Mann M, et al: Inhibition of neointimal cell bcl-x expression induces apoptosis and regression of vascular disease. Nat Med 4:222-227, 1998
10. Kockx M: Apoptosis in the atherosclerotic plaque: Quantitative and qualitative apects. Arterioscler Thromb Vasc Biol 18:1519-1522, 1998
11. Bjorkerud S, Bjorkerud B: Apoptosis is abundant in human atherosclerotic lesions, especially in inflammatory cells (macrophages and T cells), and may contribute to the accumulation of gruel and plaque instability. Am J Pathol 149:367-380, 1996
12. Cai W, Devaux B, Schaper W, et al: The role of Fas/APO 1 and apoptosis in the development of human atherosclerotic lesions. Atherosclerosis 131:177-186, 1997
13. Geng Y: Regulation of programmed cell death or apoptosis in atherosclerosis. Heart Vessels 12:S76-S80, 1997 (suppl)
14. Nagata S, Goldstein P: The FAS death factor. Science 267:1449-1456, 1995
15. Fukuo K, Nakahashi T, Nomura S, et al: Possible participation of Fas-mediated apoptosis in the mechanism of atherosclerosis. Gerontology 43:35-42, 1997
16. Geng Y, Henderson L, Levesque E, et al: Fas is expressed in human atherosclerotic intima and promotes apoptosis of cytokine-primed human vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 17:2200-2208, 1997
17. Cascino I, Papoff G, Eramo A, et al: Soluble Fas/APO-1 splicing variants and apoptosis. Front Biosci 1:12-18, 1996
18. Sato M, Konuma T, Yanagisawa N, et al: Fas-Fas ligand system in the peripheral blood of patients with renal diseases. Nephron 85:107-113, 2000
19. Perianayagam MC, Murray SL, Balakrishnan VS, et al: Serum soluble Fas (CD95) and Fas ligand profiles in chronic kidney failure. J Lab Clin Med 136:320-327, 2000
20. Sardenberg C, Dalboni MA, Watanabe R, et al: Soluble Fas (sFas): A new marker of inflammation in dialysis patients? J Am Soc Nephrol 12:410A, 2001 (abstr)
21. Masse M, Hébert M, Vigneault N, et al: Markers of apoptosis and inflammation are predictive of cardiovascular disease in hemodialysis patients. J Am Soc Nephrol 11:286A, 2000 (abstr)
22. Hebert MJ, Masse M, Vigneault N, et al: Soluble Fas is a marker of coronary artery disease in patients with end-stage renal disease. Am J Kidney Dis 38:1271-1276, 2001
23. Collins AJ, Li S, Ma JZ, et al: Cardiovascular disease in end-stage renal disease patients. Am J Kidney Dis 38:S26-S29, 2001 (suppl 1)
24. Parfrey P: Cardiac and cerebrovascular disease in chronic uremia. Am J Kidney Dis 21:77-80, 1993
25. Levey AS, Beto JA, Coronado BE, et al: Controlling the epidemic of cardiovascular disease in chronic renal disease: What do we know? What do we need to learn? Where do we go from here? National Kidney Foundation Task Force on Cardiovascular Disease. Am J Kidney Dis 32:853-906, 1998
26. Parfrey PS, Foley RN: The clinical epidemiology of cardiac disease in chronic renal failure. J Am Soc Nephrol 10:1606-1615, 1999
27. Zimmermann J, Herrlinger S, Pruy A, et al: Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int 55:648-658, 1999
28. Zoccali C, Benedetto FA, Mallamaci F, et al: Inflammation is associated with carotid atherosclerosis in dialysis patients. Creed Investigators. Cardiovascular Risk Extended Evaluation in Dialysis Patients. J Hypertens 18:1207-1213, 2000
29. Ashkenazi A, Dixit VM: Death receptors: Signaling and modulation. Science 281:1305-1308, 1998
30. Nagata S: Apoptosis by death factor. Cell 88:355-365, 1997
31. Cascino I, Fiucci G, Papoff G, et al: Three functional soluble forms of the human apoptosis-inducing Fas molecule are produced by alternative splicing. J Immunol 154:2706-2713, 1995
32. Geng YJ, Libby P: Progression of atheroma: A struggle between death and procreation. Arterioscler Thromb Vasc Biol 22:1370-1380, 2002
33. Rothlein R, Mainolfi EA, Czajkowski M, et al: A form of circulating ICAM-1 in human serum. J Immunol 147:3788-3793, 1991
34. van der Wal A, Das P, Tigges A, et al: Adhesion molecules on the endothelium and mononuclear cells in human atherosclerotic lesions. Am J Pathol 141:1427-1433, 1992
35. Blake GJ, Ridker PM: Novel clinical markers of vascular wall inflammation. Circ Res 89:763-771, 2001
36. Shimizu M, Fukuo K, Nagata S, et al: Increased plasma levels of the soluble form of Fas ligand in patients with acute myocardial infarction and unstable angina pectoris. J Am Coll Cardiol 39:585-590, 2002
37. Fiorina P, Astorri E, Albertini R, et al: Soluble antiapoptotic molecules and immune activation in chronic heart failure and unstable angina pectoris. J Clin Immunol 20:101-106, 2000
38. Ohtsuka T, Hamada M, Sasaki O, et al: Clinical implications of circulating soluble FAS and FAS-ligand in patients with acute myocardial infarction. Coron Artery Dis 10:221-225, 1999
39. Sata M, Luo Z, Walsh K: Fas ligand overexpression on allograft endothelium inhibits inflammatory cell infiltration and transplant-associated intimal hyperplasia. J Immunol 166:6964-6971, 2001
40. Amant C, Holm P, Xu SH, et al: Estrogen receptor mediated, nitric oxide-dependent modulation of the immunologic barrier function of the endothelium: Regulation of Fas ligand expression by estradiol. Circulation 104:2576-2581, 2001
41. Huikuri HV, Castellanos A, Myerburg RJ: Sudden death due to cardiac arrhythmias. N Engl J Med 345:1473-1482, 2001
42. Okura T, Watanabe S, Jiang Y, et al: Soluble Fas ligand and atherosclerosis in hypertensive patients. J Hypertens 20:895-898, 2002